New combo aims to beat bladder cancer without removing the bladder
NCT ID NCT07296705
First seen Jan 05, 2026 · Last updated Jun 17, 2026 · Updated 26 times
Summary
This study tests whether a combination of two targeted drugs (zanidatamab and tislelizumab) plus chemotherapy can shrink HER2-positive muscle-invasive bladder cancer enough to avoid bladder removal. About 25 adults with stage T2-T4a bladder cancer will receive the treatment before deciding if the bladder can be safely preserved. The goal is to keep the bladder intact while controlling the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CANCER (MIBC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Putian University
RECRUITINGPutian, Fujian, 351106, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fujian Provincial Hospital Affiliated to Fuzhou University
RECRUITINGFuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, Jiangxi, 330029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Quanzhou First Hospital Affiliated to Fujian Medical University
RECRUITINGQuanzhou, Fujian, 362002, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sanming First Hospital
RECRUITINGSanming, Fujian, 365099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affi liated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, 361003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, 325035, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhangzhou Affiliated Hospital to Fujian Medical University
RECRUITINGZhangzhou, Fujian, 363000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.